貨號(hào)：GS40430

Metelimumab is a fully human monoclonal antibody that specifically targets transforming growth factor-beta 1 (TGF?β1), a key profibrotic cytokine. By binding to TGF?β1, it neutralizes the cytokine and prevents it from interacting with its receptors, thereby blocking downstream Smad?dependent signaling pathways that drive fibroblast activation, collagen production, and tissue fibrosis. It was developed as a potential anti?fibrotic therapy and was clinically evaluated for the treatment of diffuse cutaneous systemic sclerosis (scleroderma), a disease characterized by excessive collagen deposition and progressive skin thickening. However, its development was discontinued due to lack of efficacy in Phase II trials.